secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001034842-26-000027
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Lilly terminates ocadusertib license deal with Rigel; effective June 15, 2026
-----------------------------------------------------------------------------

- Lilly elected to terminate the License and Collaboration Agreement for ocadusertib on April 16, 2026; effective June 15, 2026.
- Rigel will regain full rights to ocadusertib and associated RIPK1 inhibitors after termination.
- CNS disease program under the agreement was already terminated effective November 2025.
- Rigel does not expect to receive any future milestones or royalties under the terminated agreement.
- Rigel is evaluating the impact; no financial guidance or changes provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000027/0001034842-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000027/rigl-20260416.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer